That superhero is a gene called TP53, and for decades scientists have known it as the “guardian of the genome.” In a healthy cell, TP53 acts like both a brake and an emergency stop button. When DNA ...

The FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

NEW YORK – Pfizer is hoping to seek US regulatory approval for the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) plus chemotherapy as a first-line treatment for BRAF ...

Researchers have created the first complete map showing how hundreds of mutations in a key cancer gene affect tumor growth. By testing every possible mutation in a critical hotspot, they found that ...

The sum of diameters of all tumour foci, reflecting the intrathyroidal tumour burden, was an independent and more informative prognostic marker of treatment response than the mere presence or number ...

Multicenter, nonrandomized clinical trial to evaluate the efficacy and toxicity of a combination of targeted therapy and chemotherapy in the second-line treatment of patients with metastatic ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer led to a significant improvement in overall ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Differentiated thyroid cancer is the most frequently diagnosed thyroid cancer in the U.S. Recently, the American Thyroid Association (ATA) released new practice guidelines for Differentiated thyroid ...